Enveric out-licenses EB-002 to MycoMedica for up to $62M milestones plus royalties

Enveric Biosciences, Inc.

Exclusive global license for EB-002 (EVM201) to treat neuropsychiatric disorders.
Enveric receives modest upfront payments; eligible for up to $62M in development/sales milestones.
Tiered single-digit royalties on all future sales; MycoMedica has buyout options.
Enveric will focus resources on lead candidate EB-003, targeting IND filing in 2025.
MycoMedica assumes all future preclinical, clinical, and commercial development costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.